-
1
GLP-1 receptor agonists (GLP-1RAs) are primarily used for type 2 diabetes and obesity, with cardiovascular benefits established in clinical trials.
-
2
GLP-1RAs may influence neurological diseases through mechanisms like metabolic dysfunction, inflammation, oxidative stress, and neurovascular injury.
-
3
Preclinical studies indicate GLP-1RAs can reduce neuroinflammation and oxidative stress, supporting mitochondrial function and blood-brain barrier integrity.
-
4
Clinical findings on GLP-1RAs in neurological disorders are inconsistent, with some studies showing potential benefits in Parkinson's but mixed results in Alzheimer's.
-
5
Challenges in translating GLP-1RAs to neurological practice include disease heterogeneity, limited trials with neurological endpoints, and variable CNS exposure.
